{"article_link": "https://doi.org/10.1038/s41586-021-04278-5", "data": [{"id": "data_1", "omics": "Genomics", "link": "", "format": "WES, sWGS", "source": "European Genome-Phenome Archive (EGA)", "public_id": "EGAS00001004582"}, {"id": "data_2", "omics": "Transcriptomics", "link": "", "format": "RNA-seq", "source": "European Genome-Phenome Archive (EGA)", "public_id": "EGAS00001004582"}, {"id": "data_3", "omics": "Digital Pathology", "link": "", "format": "Digital Pathology Images", "source": "Cambridge University Hospitals NHS Foundation Trust", "public_id": "Not publicly archived"}], "analyses": [{"id": "analysis_1", "analysis_name": "Differential analysis", "analysis_data": ["data_1", "data_2"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}}, {"id": "analysis_2", "analysis_name": "Gene set enrichment analysis", "analysis_data": ["data_2"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "value": {"G2M checkpoint": "P=0.004 (HER2−)", "E2F targets": "P=0.0001 (HER2−)", "APOBEC signature": "P=0.0001 (HER2−)"}}, {"id": "analysis_3", "analysis_name": "Copy number calling", "analysis_data": ["data_1"], "label": {"Response": ["pCR", "Residual Disease"]}, "value": {"Copy number alterations": "P=0.0002"}}, {"id": "analysis_4", "analysis_name": "Mutational signature decomposition", "analysis_data": ["data_1"], "label": {"Response": ["pCR", "Residual Disease"]}, "value": {"HRD score": "P=0.00001", "APOBEC signature": "P=0.00001"}}, {"id": "analysis_5", "analysis_name": "HLA typing and neoantigen calling", "analysis_data": ["data_1", "data_2"], "label": {"Response": ["pCR", "Residual Disease"]}, "value": {"Neoantigen binding affinity": "<500 nM (vs. wild-type)"}}, {"id": "analysis_6", "analysis_name": "iC10 classification", "analysis_data": ["data_1", "data_2"], "label": {"Response": ["pCR", "Residual Disease"]}, "value": {"Overrepresentation": "iC10 subtypes"}}, {"id": "analysis_7", "analysis_name": "Immune microenvironment characterization", "analysis_data": ["data_1", "data_2", "data_3"], "label": {"Response": ["pCR", "Residual Disease"]}, "value": {"T cell dysfunction": "P=0.006 (HER2−)", "T cell exclusion": "P=0.0009", "Cytolytic activity score": "R²=0.4"}}, {"id": "analysis_8", "analysis_name": "Machine learning model", "analysis_data": ["data_1", "data_2", "data_3"], "label": {"pCR vs. Residual Disease": []}, "value": {"AUC": "0.87 (external validation: 75 cases)", "Features": ["age", "lymphocyte density", "PGR expression", "ERBB2 expression", "Tumor mutation burden", "HLA LOH", "Anthracycline therapy", "Taxane therapy sequence", "Anti-HER2 therapy", "Number of chemotherapy cycles"]}}, {"id": "analysis_9", "analysis_name": "Gene set variation analysis (GSVA)", "analysis_data": ["data_2"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "value": {"GGI score": "Monotonic association P=0.0001", "STAT1 score": "Monotonic association P=0.00001"}}], "results": [{"analysis_id": "analysis_1", "metrics": "Fold change", "value": {"TP53": "OR=2.9", "PIK3CA": "OR=2.1"}, "features": ["TP53", "PIK3CA", "CDKN2A", "MYC", "ESR1"]}, {"analysis_id": "analysis_2", "metrics": "Normalized enrichment score", "value": {"G2M checkpoint": "1.0", "E2F targets": "0.8", "APOBEC signature": "1.1"}, "features": ["G2M checkpoint", "E2F targets", "APOBEC signature"]}, {"analysis_id": "analysis_3", "metrics": "Monotonic association", "value": {"Copy number alterations": "P=0.0002"}, "features": ["Copy number alterations"]}, {"analysis_id": "analysis_4", "metrics": "Monotonic association", "value": {"HRD score": "P=0.00001", "APOBEC signature": "P=0.00001"}, "features": ["HRD score", "APOBEC signature"]}, {"analysis_id": "analysis_5", "metrics": "Neoantigen binding affinity", "value": {"Threshold": "<500 nM (vs. wild-type)"}, "features": ["HLA LOH events", "Neoantigens"]}, {"analysis_id": "analysis_6", "metrics": "Association", "value": {"Overrepresentation": "iC10 subtypes"}, "features": ["iC10 subtypes"]}, {"analysis_id": "analysis_7", "metrics": "T cell dysfunction/exclusion metrics", "value": {"T cell dysfunction": "P=0.006 (HER2−)", "T cell exclusion": "P=0.0009", "Cytolytic activity score": "R²=0.4"}, "features": ["T cell dysfunction", "T cell exclusion", "Cytolytic activity score"]}, {"analysis_id": "analysis_8", "metrics": "AUC", "value": {"0.87": "External validation (75 cases)"}, "features": ["age", "lymphocyte density", "PGR expression", "ERBB2 expression", "Tumor mutation burden", "HLA LOH", "Anthracycline therapy", "Taxane therapy sequence", "Anti-HER2 therapy", "Number of chemotherapy cycles"]}, {"analysis_id": "analysis_9", "metrics": "Monotonic association", "value": {"GGI score": "P=0.0001", "STAT1 score": "P=0.00001"}, "features": ["GGI score", "STAT1 score"]}]}